Recombinant Mouse CXCL5 protein (rFc Tag) (HPLC verified)

种属

Mouse

纯度

>90 %, SDS-PAGE
>90 %, SEC-HPLC

标签

rFc Tag

生物活性

未测试

Cat no : Eg1636

Print datasheet

Synonyms

C-X-C motif chemokine 5, Cytokine LIX, GCP-2(1-78), GCP-2(9-78), Scyb5



产品信息

纯度 >90 %, SDS-PAGE
>90 %, SEC-HPLC
内毒素 <0.1 EU/μg protein, LAL method
生物活性
Not tested
来源 HEK293-derived Mouse CXCL5 protein Val45-Ala118 (Accession# P50228) with a rabbit IgG Fc tag at the C-terminus.
基因ID 20311
蛋白编号 P50228
预测分子量 34.3 kDa
SDS-PAGE 33-40 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

CXCL5 is a member of the ELR+ CXC chemokine family, whose members contain a highly conserved three amino acid motif (ELR+) that promotes angiogenesis and is highly associated with aberrant angiogenesis. CXCL5 is an important chemokine secreted by immune cells, such as monocytes and T lymphocytes. Recent studies indicated that CXCL5 is aberrantly expressed in >14 different types of cancer, including hepatocellular carcinoma, prostate cancer, pancreatic cancer, and gastric cancer. Antibody neutralization of CXCL5 in experimental models of human non-small-cell lung cancer decreased tumor angiogenesis and metastasis.

参考文献:

1. Robert M Strieter.et al. (2004) Semin Cancer Biol. 14(3):195-200. 2. R M Strieter.et al. (1995) J Biol Chem. 270(45):27348-57. 3. Morgan O'Hayre.et al. (2008) BiochemJ. 409(3):635-49. 4. Gildas Lepennetier.et al. (2019) J Neuroinflammation. 16(1):219. 5. Wen Zhang. Et al. (2020) Cancer Commun (Lond). 40(2-3):69-80.